WO2006096497A3 - Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients - Google Patents

Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients Download PDF

Info

Publication number
WO2006096497A3
WO2006096497A3 PCT/US2006/007571 US2006007571W WO2006096497A3 WO 2006096497 A3 WO2006096497 A3 WO 2006096497A3 US 2006007571 W US2006007571 W US 2006007571W WO 2006096497 A3 WO2006096497 A3 WO 2006096497A3
Authority
WO
WIPO (PCT)
Prior art keywords
iss
vaccines
oligonucleotides
antigens
conjugated
Prior art date
Application number
PCT/US2006/007571
Other languages
French (fr)
Other versions
WO2006096497A2 (en
Inventor
Stephen F Tuck
Roberto Rodriguez
Original Assignee
Dynavax Tech Corp
Stephen F Tuck
Roberto Rodriguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp, Stephen F Tuck, Roberto Rodriguez filed Critical Dynavax Tech Corp
Priority to AU2006220835A priority Critical patent/AU2006220835B2/en
Priority to CA002600036A priority patent/CA2600036A1/en
Priority to NZ561144A priority patent/NZ561144A/en
Priority to JP2007558260A priority patent/JP2008531722A/en
Priority to EP06736828A priority patent/EP2007421A2/en
Publication of WO2006096497A2 publication Critical patent/WO2006096497A2/en
Publication of WO2006096497A3 publication Critical patent/WO2006096497A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • A61K39/36Allergens from pollen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006Cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025Nucleotides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides compositions comprising conjugate molecules that are structurally stable at a temperature of between about 2 degrees C and 8 degrees C. In some examples, a conjugate molecule comprises an antigen, such as an allergen. In some examples, a conjugate molecule comprises the Ragweed antigen Amb a 1. The present invention provides methods for making and using such compositions. Provided herein are methods for modulating an immune response in an individual comprising administration of a composition comprising a structurally stable conjugate molecule as described herein.
PCT/US2006/007571 2005-03-04 2006-03-03 Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients WO2006096497A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2006220835A AU2006220835B2 (en) 2005-03-04 2006-03-03 Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
CA002600036A CA2600036A1 (en) 2005-03-04 2006-03-03 Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
NZ561144A NZ561144A (en) 2005-03-04 2006-03-03 Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
JP2007558260A JP2008531722A (en) 2005-03-04 2006-03-03 Composition comprising a structurally stable conjugate molecule
EP06736828A EP2007421A2 (en) 2005-03-04 2006-03-03 Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65894705P 2005-03-04 2005-03-04
US60/658,947 2005-03-04

Publications (2)

Publication Number Publication Date
WO2006096497A2 WO2006096497A2 (en) 2006-09-14
WO2006096497A3 true WO2006096497A3 (en) 2007-05-03

Family

ID=36953874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007571 WO2006096497A2 (en) 2005-03-04 2006-03-03 Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients

Country Status (10)

Country Link
US (2) US7718622B2 (en)
EP (1) EP2007421A2 (en)
JP (1) JP2008531722A (en)
KR (1) KR20070110901A (en)
CN (1) CN101171033A (en)
AU (1) AU2006220835B2 (en)
CA (1) CA2600036A1 (en)
NZ (1) NZ561144A (en)
SG (1) SG160336A1 (en)
WO (1) WO2006096497A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2487645T3 (en) * 2001-06-21 2014-08-22 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of use thereof
EP1551376A4 (en) * 2002-08-12 2010-10-06 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
JP2008531722A (en) 2005-03-04 2008-08-14 ダイナバックス テクノロジーズ コーポレイション Composition comprising a structurally stable conjugate molecule
US8252757B2 (en) 2006-11-09 2012-08-28 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US8815817B2 (en) 2008-05-15 2014-08-26 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
PL2153841T5 (en) * 2008-08-15 2016-09-30 Circassia Ltd Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
DE102009034779A1 (en) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetic analogues of bacterial lipopeptides and their application for the therapy and prophylaxis of allergic diseases
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
PL3164113T3 (en) 2014-06-04 2019-09-30 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN104181309B (en) * 2014-08-22 2016-03-02 山东博科生物产业有限公司 A kind of highly sensitive Troponin I detection kit
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015726A2 (en) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
WO2001035991A2 (en) * 1999-11-15 2001-05-25 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US6251678B1 (en) * 1999-02-05 2001-06-26 Merck & Co., Inc. Human papillomavirus vaccine formulations
WO2003000922A2 (en) * 2001-06-21 2003-01-03 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
WO2003106644A2 (en) * 2002-06-14 2003-12-24 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (rsv) antibody formulations
WO2004060396A2 (en) * 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705684A (en) 1985-05-31 1987-11-10 The University Of Tennessee Research Corporation Synthetic M proteins - streptococci type 6
AU705889B2 (en) 1993-08-26 1999-06-03 Regents Of The University Of California, The Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
WO1997028259A1 (en) 1996-01-30 1997-08-07 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA.
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69840850D1 (en) 1997-06-06 2009-07-09 Dynavax Tech Corp INHIBITORS OF IMMUNSTIMULATORY DNA SEQUENCE ACTIVITY
US20040006034A1 (en) 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
AU757175B2 (en) * 1997-09-05 2003-02-06 Regents Of The University Of California, The Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
ATE326239T1 (en) 1998-09-18 2006-06-15 Dynavax Tech Corp METHODS FOR TREATING IG-E ASSOCIATED DISEASES AND COMPOSITIONS FOR USE IN SUCH METHODS
AU6425999A (en) 1998-10-09 2000-05-01 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
FR2790955B1 (en) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT
US6737066B1 (en) * 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
ATE419869T1 (en) 1999-08-19 2009-01-15 Dynavax Tech Corp METHOD FOR MODULATING AN IMMUNE RESPONSE USING IMMUNSTIMULATIVE SEQUENCES AND COMPOSITIONS THEREOF
DK1221955T3 (en) * 1999-09-25 2006-01-30 Univ Iowa Res Found Immune-stimulating nucleic acid
ATE378348T1 (en) * 2000-01-14 2007-11-15 Us Health OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE
WO2001055341A2 (en) * 2000-01-31 2001-08-02 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
CA2399550A1 (en) * 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
CA2404041A1 (en) * 2000-03-28 2001-10-04 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
US20020142978A1 (en) 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
US6893821B2 (en) * 2000-05-05 2005-05-17 The Regents Of The University Of California Agents that modulate DNA-PK activity and methods of use thereof
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
WO2002052002A2 (en) 2000-12-27 2002-07-04 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US20040132677A1 (en) 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
EP1420829A4 (en) 2001-08-07 2006-05-17 Dynavax Tech Corp Immunomodulatory compositions, formulations, and methods for use thereof
WO2003027313A2 (en) * 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
EP1455833A1 (en) * 2001-12-04 2004-09-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Chimeric molecule for the treatment of th2-like cytokine mediated disorders
US7615227B2 (en) * 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP1551376A4 (en) 2002-08-12 2010-10-06 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
CN100536853C (en) * 2002-09-13 2009-09-09 艾登尼科斯(开曼)有限公司 Ss-l-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
AU2003302743B2 (en) 2002-12-23 2008-09-04 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
ATE544772T1 (en) 2002-12-23 2012-02-15 Dynavax Tech Corp IMMUNO-STIMULATING SEQUENCE OLIGONUCLEOTIDES AND METHOD OF USE THEREOF
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
NZ553581A (en) 2004-09-01 2011-04-29 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
EP1836218A2 (en) 2004-12-17 2007-09-26 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
JP2008531722A (en) * 2005-03-04 2008-08-14 ダイナバックス テクノロジーズ コーポレイション Composition comprising a structurally stable conjugate molecule
US8815817B2 (en) * 2008-05-15 2014-08-26 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US20120177701A1 (en) * 2010-12-31 2012-07-12 Selecta Biosciences, Inc. Compositions comprising immunostimulatory nucleic acids and related methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251678B1 (en) * 1999-02-05 2001-06-26 Merck & Co., Inc. Human papillomavirus vaccine formulations
WO2001015726A2 (en) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
WO2001035991A2 (en) * 1999-11-15 2001-05-25 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2003000922A2 (en) * 2001-06-21 2003-01-03 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
WO2003106644A2 (en) * 2002-06-14 2003-12-24 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (rsv) antibody formulations
WO2004060396A2 (en) * 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIMONS ET AL: "Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 113, no. 6, June 2004 (2004-06-01), pages 1144 - 1151, XP005396559, ISSN: 0091-6749 *

Also Published As

Publication number Publication date
WO2006096497A2 (en) 2006-09-14
SG160336A1 (en) 2010-04-29
US20070036807A1 (en) 2007-02-15
AU2006220835B2 (en) 2012-01-19
CN101171033A (en) 2008-04-30
EP2007421A2 (en) 2008-12-31
USRE45196E1 (en) 2014-10-14
AU2006220835A1 (en) 2006-09-14
NZ561144A (en) 2009-09-25
JP2008531722A (en) 2008-08-14
CA2600036A1 (en) 2006-09-14
US7718622B2 (en) 2010-05-18
KR20070110901A (en) 2007-11-20

Similar Documents

Publication Publication Date Title
WO2006096497A3 (en) Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2006067632A3 (en) Saccharide conjugate vaccines
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2001035991A3 (en) Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
MA30066B1 (en) VACCINE
WO2006116475A3 (en) Immunostimulatory compositions
WO2004041157A3 (en) Group b streptococcus vaccine
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
DK2343320T3 (en) ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF
WO2006034292A3 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2005055950A3 (en) Glycopegylated factor ix
WO2006031811A3 (en) Glycopegylated interferon alpha
IL155283A0 (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
SE0202110D0 (en) Iscom preparation and use thereof
WO2010146598A3 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
WO2007041216A3 (en) Plasmodium liver stage antigens
WO2010141312A3 (en) Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
EP3381445A3 (en) Aqueous formulation of antibody stablised by antioxidants for parenteral administration
WO2007116409A3 (en) Improved vaccines comprising multimeric hsp60 peptide carriers
Gaertner et al. Efficient orthogonal bioconjugation of dendrimers for synthesis of bioactive nanoparticles
WO2006105993A3 (en) Method for shielding functional sites or epitopes on proteins
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
Demircan et al. Biotin Functionalized Self‐Assembled Peptide Nanofiber as an Adjuvant for Immunomodulatory Response
WO2005007673A3 (en) Immunogenic peptides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680015107.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006220835

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007558260

Country of ref document: JP

Ref document number: 561144

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2600036

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006220835

Country of ref document: AU

Date of ref document: 20060303

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006736828

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1020077022686

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06736828

Country of ref document: EP

Kind code of ref document: A2